Deal covers Genomic Health’s Oncotype DX breast cancer assay.

Genomic Health signed an exclusive agreement with Medical Solutions to distribute the company’s Oncotype DX breast cancer assay in the U.K.

“We view this U.K. partnership as an important milestone in making our Oncotype DX breast cancer assay more widely available,” said Chu Chang, Genomic Health’s vp of business development. “We plan to continue to realize opportunities to broaden access to our test to patients outside of the United States who may benefit from the individualized information Oncotype DX results provide.”

Oncotype DX is currently offered for sale in Israel under a testing and services agreement with Teva Pharmaceutical, and in Japan under an agreement with SRL. Patient tumor samples from these and numerous other countries around the world are analyzed in Genomic Health’s reference laboratory in Redwood City, CA.

Previous article454 Life Sciences and Baylor College of Medicine Sequence Genome for Less than $1M
Next articlePeregrine Pharmaceuticals Inks $50M mAb Development Deal with Dios Therapeutics